“A study released [Friday in The Lancet] shows that an oral cholera vaccine made in India is the first such vaccine to offer significant protection for five years, while another new report says the vaccine was well-accepted in an immunization campaign last year in the African country of Guinea,” CIDRAP News reports. “The vaccine, Shanchol, is made by Shantha Biotechnics and was endorsed by the [WHO] in 2011,” the news service notes, adding, “The cumulative protective efficacy of the vaccine was 65 percent … , and year-by-year estimates showed no evidence of a decline in efficacy, the report says.” The other study, published in PLOS Neglected Tropical Diseases, “focused on a mass cholera vaccination campaign launched by Guinea’s Ministry of Health in 2012, with support from Médecins Sans Frontières, to help battle the country’s ongoing cholera epidemic,” CIDRAP states, noting the report authors said “that although oral cholera vaccines should not be viewed as a long-term solution for global cholera control, they should be integrated as an additional tool into the response” (Roos, 10/18).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.